OncoMatch/Clinical Trials/NCT05043701

Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma

Is NCT05043701 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Personalized drug combination for recurrent glioblastoma.

Early Phase 1RecruitingOslo University HospitalNCT05043701Data as of May 2026

Treatment: Personalized drug combination — A study to determine the feasibility and safety of individualized cancer stem cell targeted therapy based on high-throughput functional profiling of FDA/EMA-approved drugs in patients with GBM that has recurred or progressed following standards-of-care (RT, TMZ).

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

adequate bone marrow function

Liver function

adequate liver function

Cardiac function

adequate heart function

Adequate bone marrow, liver and heart function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify